Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer.

Lara ParacchiniLuca Beltrame Tommaso GrassiAlessia InglesiRobert FruscioFabio Landoni Davide IppolitoMartina Delle MarchetteMariachiara PadernoAdorni MarcoMarta JaconiChiara RomualdiMaurizio D'IncalciGiulia SiravegnaSergio Marchini

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Our results support the notion that sWGS is an inexpensive and useful tool for the genomic analysis of ctDNA in patients with HGS-EOC to monitor disease evolution and to anticipate relapse better than serum CA-125, the routinely used clinical biomarker.See related commentary by Dhani, p. 2372.

Keyphrases

circulating tumor
copy number
high grade
genome wide
mitochondrial dna
dna methylation
low grade
cell free
circulating tumor cells
gene expression
free survival
protein kinase